Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05991219

Screening and Secondary Prevention Rheumatic Heart Disease Study

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Rheumatic Heart Disease Bacterial Infections Bacterial Infections and Mycoses Cardiovascular Diseases Gram-Positive Bacterial Infections Heart Diseases Infections Rheumatic Fever Streptococcal Infections

Age range

10 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Institute of Cardiovascular Diseases (NICVD)

Karachi, Sindh, 75510, Pakistan

Location status: Recruiting

About this study

Screening for RHD should be carried out since it is a major health concern that has been shown to have a treatable and detectable latent stage that can be diagnosed using a simple sensitive test (point of care ultrasound) and early treatment (secondary prevention using antibiotic prophylaxis) can provide a better outcome (slow progression of disease) in a cost effective way. The investigators aim to study the Incidence and Prevalence of RHD in community and school settings and aim to intervene depending on the stage the disease is picked up in.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rural communities in Sindh

Exclusion criteria

  • Refused to participate in the study

Treatment and study plan

Primary outcomes

  1. Rheumatic heart disease

    Time frame: At the time of screening echocardiogram

    Number of patients

Study contacts

Contact information is provided by the study sponsor or research team.

Sabha Bhatti, MD

CONTACT

[email protected]

+92 335 5554346

Sponsors and collaborators

Lead sponsor

National Institute of Cardiovascular Diseases, Pakistan

Other

Registry information

Official study title

Screening and Secondary Prevention Rheumatic Heart Disease

Acronym: S2-RHD

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Aug 14, 2023
Registry last updated
Aug 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.